Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Tekmira Pharmaceuticals Announces RNAi Research Collaboration With Bristol-Myers Squibb

Abstract:
Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today a research collaboration with Bristol-Myers Squibb (NYSE:BMY) using Tekmira's SNALP technology to deliver small interfering RNAs (siRNAs) to specific organs and tissues outside of the liver.

Tekmira Pharmaceuticals Announces RNAi Research Collaboration With Bristol-Myers Squibb

VANCOUVER, BC, Canada | Posted on August 13th, 2008

The relationship between Tekmira and Bristol-Myers Squibb builds upon earlier work conducted at Bristol-Myers Squibb using siRNA delivery technology provided by privately held Protiva Biotherapeutics Inc. In May, Protiva and Tekmira combined their businesses to create a leader in the field of RNAi (RNA interference) therapeutics.

Dr. Mark J. Murray, Tekmira's President and CEO, said, "Our relationship with Bristol-Myers Squibb is consistent with our strategy to work with global pharmaceutical leaders to expand the therapeutic potential of our leading RNAi delivery technology. At the same time, this work compliments our internal product development initiatives as we advance our own RNAi therapeutics to treat serious human diseases."

The initial collaboration between Bristol-Myers Squibb and Protiva focused on validating certain gene targets using small interfering RNAs provided by Bristol-Myers Squibb and employed a number of different stable nucleic-acid lipid particle (SNALP) formulations. SNALP is Tekmira's proprietary lipid nanoparticle technology for the delivery of RNAi drugs, including siRNAs.

About RNAi and SNALP

RNAi drugs have the potential to treat human diseases by "switching-off" disease causing genes. The technology, representing one of the most promising and rapidly advancing frontiers in biology and drug discovery, was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi drugs, such as siRNA, require delivery technology to be administered systemically. In preclinical studies, Tekmira's SNALP (stable nucleic acid-lipid particles) technology has been shown to be a safe and effective way to deliver RNAi drugs to disease sites. Tekmira believes it has a leading intellectual property position in the field of siRNA delivery.

####

About Tekmira Pharmaceuticals Corporation
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

Forward-Looking Statements and Information

There are forward-looking statements and information contained herein that are not based on historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions, and the negative of such expressions. These statements are only predictions.

Forward-looking statements and information should be considered carefully. Undue reliance should not be placed on forward-looking statements and information as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements and information involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, which contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements and information will not occur and may cause actual results or events to differ materially from those anticipated in such forward-looking statements and information.

There are also other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements and information. Such factors include, among others, the stage of development of Tekmira, lack of product revenues, additional capital requirements, the need to obtain regulatory approval to commence clinical trials, risks associated with the completion of clinical trials and obtaining regulatory approval to market Tekmira's products, the safety and efficacy of Tekmira's products, the ability to protect Tekmira's intellectual property and dependence on collaborative partners.

A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira's management information circular dated May 1, 2008 available at www.sedar.com. Tekmira disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements or information contained herein to reflect future results, events or developments, except as required by law.

For more information, please click here

Contacts:
Tekmira Pharmaceuticals Corporation - Investors
Ian Mortimer
Executive Vice President and Chief Financial Officer
(604) 419-3200
or
Longview Communications Inc. - Media
David Ryan
(604) 694-6031

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Production of Organometallic Frameworks in Least Possible Time September 23rd, 2014

Engineers show light can play seesaw at the nanoscale: Discovery is another step toward faster and more energy-efficient optical devices for computation and communication September 22nd, 2014

New chip promising for tumor-targeting research September 22nd, 2014

Twisted graphene chills out: When two sheets of graphene are stacked in a special way, it is possible to cool down the graphene with a laser instead of heating it up, University of Manchester researchers have shown September 22nd, 2014

Nanomedicine

Production of Organometallic Frameworks in Least Possible Time September 23rd, 2014

Engineered proteins stick like glue — even in water: New adhesives based on mussel proteins could be useful for naval or medical applications September 22nd, 2014

New chip promising for tumor-targeting research September 22nd, 2014

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

Announcements

Production of Organometallic Frameworks in Least Possible Time September 23rd, 2014

New chip promising for tumor-targeting research September 22nd, 2014

Twisted graphene chills out: When two sheets of graphene are stacked in a special way, it is possible to cool down the graphene with a laser instead of heating it up, University of Manchester researchers have shown September 22nd, 2014

New star-shaped molecule breakthrough: Scientists at The University of Manchester have generated a new star-shaped molecule made up of interlocking rings, which is the most complex of its kind ever created September 22nd, 2014

Patents/IP/Tech Transfer/Licensing

‘Small’ transformation yields big changes September 16th, 2014

Berkeley Lab Licenses Boron Nitride Nanotube Technology: New material has unique mechanical and electronic properties September 13th, 2014

Secure Computing for the ‘Everyman': Quantum computing goes to market in tech transfer agreement with Allied Minds September 2nd, 2014

New analytical technology reveals 'nanomechanical' surface traits August 29th, 2014

Alliances/Partnerships/Distributorships

IEEE International Electron Devices Meeting To Celebrate 60th Anniversary as The Leading Technical Conference for Advanced Semiconductor Devices September 18th, 2014

Biosensors Get a Boost from Graphene Partnership: $5 Million Investment Supports Dozens of Jobs and Development of 300mm Fabrication Process and Wafer Transfer Facility September 18th, 2014

Toward making lithium-sulfur batteries a commercial reality for a bigger energy punch September 17th, 2014

NEI Corporation and PneumatiCoat Technologies Sign Agreement to Jointly Develop and Market New Materials for Lithium-ion Batteries September 12th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE